Actualités Proteonomix Inc (CE) - PROT | Actions OTCMarkets

Outils de qualité professionnelle, pour des investisseurs individuels.

Proteonomix Settles Litigation

Proteonomix Settles Litigation PR Newswire PARAMUS, N.J., April 1, 2013 PARAMUS, N.J., April 1, 2013 /PRNewswire/ -- Proteonomix, Inc. (OTC:...

Proteonomix Announces Extension Of Deadline

Proteonomix Announces Extension Of Deadline /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prn...

Proteonomix To Require Physical Exchange Of Certificates

Proteonomix To Require Physical Exchange Of Certificates /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:b...

Proteonomix Announces Restructuring

Proteonomix Announces Restructuring /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a {...

Proteonomix Updates Status Of UMK-121 Testing

Proteonomix Updates Status Of UMK-121 Testing /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.p...

Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121

Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121 /* Style Definitions...

Termination of Registration of a Class of Security Under Section 12(g) (15-12g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Proteonomix, Inc. Announces Finalizing ECRF for Its Clinical Trial of UMK 121 in Patients with End Stage Liver Disease

Proteonomix, Inc. Announces Finalizing ECRF for Its Clinical Trial of UMK 121 in Patients with End Stage Liver Disease /* Style Definitions...

Proteonomix, Inc. Announces Its Clinical Trial of UMK-121 in Patients with End Stage Liver Disease Has Been Listed on Clinica...

Proteonomix, Inc. Announces Its Clinical Trial of UMK-121 in Patients with End Stage Liver Disease Has Been Listed on ClinicalTrials.gov /...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Proteonomix Inc (CE) (PROT)

Outils de qualité professionnelle, pour des investisseurs individuels.

PROT Actualités

Proteonomix Settles Litigation

Proteonomix Announces Extension Of Deadline

Proteonomix To Require Physical Exchange Of Certificates

Proteonomix Announces Restructuring

Proteonomix Updates Status Of UMK-121 Testing

Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121

Termination of Registration of a Class of Security Under Section 12(g) (15-12g)

Proteonomix, Inc. Announces Finalizing ECRF for Its Clinical Trial of UMK 121 in Patients with End Stage Liver Disease

Proteonomix, Inc. Announces Its Clinical Trial of UMK-121 in Patients with End Stage Liver Disease Has Been Listed on Clinica...

- Current report filing (8-K)

Proteonomix, Inc. Announces IRB Approval for Its Clinical Trial of UMK-121 in Patients with End Stage Liver Disease

- Amended Quarterly Report (10-Q/A)

- Amended Quarterly Report (10-Q/A)

- Current report filing (8-K)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Proteonomix Inc (CE) (PROT) Actualités

Proteonomix Inc (CE) (PROT)

Outils de qualité professionnelle, pour des investisseurs individuels.

PROT Actualités

Proteonomix Settles Litigation

Proteonomix Announces Extension Of Deadline

Proteonomix To Require Physical Exchange Of Certificates

Proteonomix Announces Restructuring

Proteonomix Updates Status Of UMK-121 Testing

Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121

Termination of Registration of a Class of Security Under Section 12(g) (15-12g)

Proteonomix, Inc. Announces Finalizing ECRF for Its Clinical Trial of UMK 121 in Patients with End Stage Liver Disease

Proteonomix, Inc. Announces Its Clinical Trial of UMK-121 in Patients with End Stage Liver Disease Has Been Listed on Clinica...

- Current report filing (8-K)

Proteonomix, Inc. Announces IRB Approval for Its Clinical Trial of UMK-121 in Patients with End Stage Liver Disease

- Amended Quarterly Report (10-Q/A)

- Amended Quarterly Report (10-Q/A)

- Current report filing (8-K)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application